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Summal'y 
After loss of expression of a major histocompatibility complex class I K k allele, the escape variant 
of an immunogenic tumor grows progressively in normal mice. This progressor variant is resistant 
to killing by cytotoxic T  lymphocytes (CTLs) directed against the A and B antigens presented 
by K k.  Although  the variant  retains  the expression of the D k allele  and is sensitive to CTLs 
directed against the C  antigen presented by D k, the variant failed to induce CTLs to this antigen 
in vivo. Instead,  the variant induced CD8 + T  cells directed to the A antigen.  This was shown 
at the molecular level by T cell receptor fl chain sequence analysis of the responding cells. Further 
evidence for the presence of A  antigen  in the variant  came from the finding  that  spleen cells 
of mice injected intraperitoneally with the variant tumor cells were primed for an anti-A CD8 ~ 
CTL response in vivo. Thus, in contrast to other variants that lost a target antigen and induced 
a CTL response to remaining target antigens, the K k loss variant continued to induce an immune 
response to a tumor antigen that is no longer presented on the tumor cell surface.  Even though 
the variant escapes in a single step because an effective CTL response to secondary antigens is 
prevented, these secondary antigens remain as potential targets ofimmunotherapy on the variant's 
cell surface. 
M 
urine ultraviolet (UV)-induced tumors can possess mul- 
tiple antigens that are not found on other tumors or 
normal  autologous  control  cells  (1,  2),  and  several  studies 
have suggested that human cancers also commonly express 
multiple antigens (for a review see reference 3). Multiple an- 
tigens on tumors display a hierarchy of antigenicity such that 
at any one time the host usually responds to only one of sev- 
eral antigens displayed simultaneously on the tumor surface 
(4, 5). If the tumor loses the immunodominant  antigen, the 
variant becomes a potential  target for immune destruction 
by the host because one of the remaining  antigens  on the 
variant  takes over the dominant  role as the  target  antigen 
(5). Thus, immunodominance leads to a pecking order with 
sequential targeting and sequential loss of multiple tumor- 
specific antigens which may result at the end in highly malig- 
nant cancer variants that lack CTL-recognized target antigens. 
Therefore,  loss of a single antigen  may not lead to perma- 
nent  immune  escape since the selection process is repeated 
for consecutive variants until antigens that induce CTL re- 
sponses are no longer  present. 
This paper shows that immunodominance leads to a quite 
different course of events when  tumor  cells retain  tumor- 
specific antigens but lose expression of a MHC class I restric- 
tion molecule that  presents the dominant  antigen.  Loss of 
expression of all MHC class I from murine or human cancers 
would  result  in  complete  tumor  cell  resistance  to  CTL- 
mediated lysis (6), but such changes are rare.  By contrast, 
selective loss of one restriction element is frequently found 
(7-11), but so far there has been no model of how a single 
allelic loss might enable a tumor to escape immune destruc- 
tion since it is unlikely that presentation of multiple antigens 
is restricted by a single allele. In this study, we find that loss 
of a single allele  of MHC class I may be sufficient for the 
tumor  to permanently  escape destruction by the host in a 
single  step. 
Using  an  H-2K  k loss variant  of a  UV-induced  murine 
tumor expressing multiple antigens, we demonstrate that the 
variant that has lost only the restriction element for the im- 
munodominant  antigen continues to induce a CD8 + T cell 
response to that antigen, even though the variant cannot be 
lysed by CTLs specific for this antigen.  This immunodomi- 
nance  impedes  responsiveness  to  antigens  on  the  tumor 
presented by other restriction  elements and thereby allows 
the tumor to escape the host's immune response in a single 
step despite retaining  other tumor-specific antigens  as potential 
targets  for immune  destruction. 
Materials and Methods 
Mice.  5-10-wk-old germ-free-derived  C3H/HeN/MTV-  fe- 
males were purchased from the National Cancer Institute Frederick 
Cancer Research Facility (Bethesda, MD) and were maintained as 
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Facility at the University of Chicago in laminar flow hoods, given 
sterile acidified water, and fed autoclaved food (5010 Rodent labo- 
ratory diet;  Purina,  Inc., St. Louis,  MO). 
Tumor Cell Lines.  Derivation of UV-induced and spontaneous 
tumors in C3H/HeN mice has been described  (1, 2). The regressor 
tumors used in this study are strongly immunogenic in that these 
tumors, when transplanted  into young syngeneic mice, grow during 
the first 10 d and then regress.  These tumors grow progressively 
in nude mice and kill by infiltrative growth without macroscopic 
evidence of distant metastases. VAR1, VAR3, and VAR4 are an- 
tigen loss variants derived from the parental 6130 regressor fibrosar- 
coma (2).  These variants can grow progressively in normal mice. 
All cell lines were cultured in MEM (Gibco Laboratories, Grand 
Island, NY) supplemented with 10% heat inactivated FCS (Gibco 
Laboratories) and 1% penicillin/streptomycin (600-5140AG;  Gibco 
Laboratories) (CMEM) 1. 
Induction of Peritoneal Exudate Lymphocytes (PELs).  3  x  106- 
1  x  107 tumor cells were injected four times intraperitoneally at 
3-d intervals as described (12). 2 d after the final injection, the mice 
were killed by cervical dislocation.  5 ml of CMEM or PBS with 
1% FCS was injected intraperitoneally and cells were removed by 
peritoneal lavage. 
Mixed Lymphocyte-Tumor Cell Cultures (MLTC).  Mice were im- 
munized by injecting  107  tumor cells  intraperitoneally.  Spleens 
from naive and immunized mice were aseptically removed 7-10 d 
after the injection and dispersed into single cell suspensions with 
sterile glass tissue grinders. RBCs were lysed with 0.83% (wt/vol) 
Tris-ammonium chloride and washed twice with CMEM. Tumor 
cells were treated with mitomycin C (Sigma Chemical Co., St. Louis, 
MO) for 45 min at 37~  and washed three times. Culture con- 
sisted of 8  x  106 responder spleen cells and 4  x  104 stimulators. 
These cells were cocultured in 3.5 ml of RPMI 1640 (Gibco Labora- 
tories)  supplemented with  10%  non-heat  inactivated FCS  (pre- 
screened from Gibco Laboratories),  1%  penicillin/streptomycin, 
0.1%  gentamycin (Gibco Laboratories) and  5  x  10 -s M  2-ME 
(Calbiochem Novabiochem, La Jolla,  CA). Culture vessels were 
16  x  125 mm round-bottomed tissue culture tubes (Falcon  Lab- 
ware, Oxnard, CA). Cultures were incubated for 6 d at 37~  5% 
CO2,  humidified atmosphere as has been described (1). 
Generation  and  Maintenance  of  Cytolytic  T  Cell  Lines  and 
Clones.  Methods for generating and maintaining CTL lines and 
clones have been described  (1). Briefly, mice were primed with 107 
tumor cells intraperitoneaUy.  Spleens from these immune mice were 
used as responder cells in MLTC with the immunizing tumor cells 
as the stimulators.  The CTLs were tested in a SlCr-release assay 
for cytotoxicity and specificity.  Long-term CTL lines  and clones 
were passaged in V-bottomed 96-well nontissue culture treated plates 
(Linbro, McLean, VA) or 24-well tissue culture plates (Costar Corp., 
Cambridge, MA). To pass CTLs in 96-well plates,  106 irradiated 
(2,000 rad) syngeneic spleen  filter cells, 2  x  104 CTL, and 2  x 
103 mitomycin C-treated stimulator cells were mixed and added 
to each well in 200/~1  of CTL passage medium. For passage of 
CTLs in 24-well plates,  10  s CTLs, 5  x  106 irradiated (2,000 rad) 
syngeneic spleen cells, and 2.5  x  104 mitomycin C-treated tumor 
cells were mixed in 1.5 ml of CTL passage medium (RPMI 1640, 
33% [vol/vol] supernatant from a secondary MLC as a source of 
T cell growth factor [13], 10% non-heat inactivated FCS, 1% pen- 
1 Abbreviations used in this paper: CMEM, MEM supplemented with 10% 
FCS, 1% penicillin/streptomycin; MLTC, mixed lymphocyte tumor cell 
culture; PEL, peritoneal exudate lymphocyte. 
icillinAtreptomycin, 0.1% gentamycin, and 5  x  10 -s M  2-ME). 
BS1 and PD4 are two anti-A specific CTL clones derived from im- 
munizations with the parental 6130 tumor (kind gifts from B. Start 
and P. Dubey, The University of Chicago). 
SlCr-release Assay.  Cytotoxicity of CTLs was determined in a 
4.5-h SlCr-release  assay, as described (14). Briefly,  effectors  from 
MLTCs, CTL clones and PELs were serially diluted in V-bottomed, 
flexible 96-well plates (Dynatech Laboratories,  Inc., Chantilly, VA) 
in 100/~1 of CMEM. Tumor cells (5  x  10  s) in 100 #1 of CMEM 
were mixed with 100 #1 of SlCr (sodium chromate at 1 mCi/ml) 
(Amersham Corp., Arlington Heights, IL) for 1 h. Labeled tumor 
targets were washed four times with CMEM, and resuspended in 
CMEM at 5  x  104 cells/ml. 100/~1 of this suspension was added 
to each well of effectors. Effectors and labeled targets were incubated 
for 4.5 h at 37~  7.5% CO2 in a humidified incubator. After in- 
cubation, 100 ~1 of supernatant from each well was collected  and 
analyzed for radioactivity by a gamma counter (Micromedic Systems 
Inc., Horsham, PA). The percent specific lysis was calculated by 
the  formula:  100x  [(experimental  release  -  spontaneous  re- 
lease)/(maximum release  -  spontaneous release)]. Spontaneous re- 
lease was <15%  of maximum release. 
Staining and Cell Sorting.  FITC-conjugated rat anti-mouse L3T4 
(anti-CD4; RM 4-5), and rat anti-mouse Ly-2 (anti-CDS; 53-6.7), 
and PE-conjugated mouse anti-mouse Vf113 (MR-12-4), were pur- 
chased from PharMingen  (San  Diego,  CA).  5  ￿  10s-1  x  106 
PELs were incubated with FITC-anti-Ly-2 and PE-anti-V~13 or 
FITC-anti-L3T4 and PE-anti-V/313 for 30 rain on ice. Cells were 
washed three times with PBS containing  1% BSA albumin and 
0.1% sodium azide (PBSA). Tumor cells were incubated with anti- 
K k (16-1-11) or anti-D k (15-5-5)  culture supernatant  (generously 
provided by Dr. A. Sant, The University of Chicago) or with PBSA 
for 30 min on ice and washed three times with PBSA. Tumor cells 
were then incubated with 1:10 dilution of FITC goat anti-mouse 
Ig (Hyclone Laboratories, Logan, UT) and washed three times with 
PBSA. Cells were analyzed on a FACScan flow cytometer (Becton 
Dickinson & Co., Mountain View, CA). Stained PELs were sorted 
on a Coulter Epics 753 (model 2566;  Argon laser run at 488 nm, 
Coulter Electronics,  Inc., Hialeah, FL). Sorted cells were incubated 
for 16 h in 24-well  plates (model 3424,  Costar Corp.), each well 
containing  10  s sorted cells,  5  x  106 irradiated  (2,000  rad)  syn- 
geneic spleen  cells,  and  2.5  x  10  4 mitomycin C-treated  tumor 
cells in  1.5  ml of CTL passage medium. 
Preparation of eDNA.  1-2  x  106 PELs were lysed in RNAzol 
VMB (Tel-Test, Inc., Friendswood,  TX) and total RNA was pre- 
pared as prescribed by the manufacturer. First-strand cDNA was 
synthesized using cDNA Synthesis System Plus (Amersham Corp.) 
according  to the manufacturer's recommendations. The cDNA reac- 
tion was heated at 90~  for 10 min before PCR amplification. 
PCR Conditions and Primers Used.  The sequence for the Vf113 
primer was as follows: 5'-GAGCTAGCGAATTCGTACTGTCTG- 
AAGCTGGAGTCACCC-3';  the  Cfl  primer  sequence  was  as 
follows:  5'-GAGCTAGCGAATTCAGCCTTTTGTTTGTTT- 
GCAATCTCT-3'.  The  The  upstream  Kk-specific  primer  and 
downstream Kk-specific exon 2 primer sequences  were as follows: 
5'-  GAGCTAGCGAATTCAAGTCTCGAATCGCCGACCGGT- 
GCG-3'  and  5'-GAGCTAGCGAATTCGCCCGCGCTCTGG- 
TTGTAGTAGCGC-3', respectively. Underlining indicates an EcoRI 
restriction site. The upstream and downstream primers for B-actin 
were as follows: 5'-TGGAATCCTGTGC~ATCCATGAAAC-3'  and 
5'-TAAAACGCAGCTCAGTAACAGTCCG-3', respectively (15). 
PCR reactions were performed using 20 pmoles of each primer 
pair, 25 nmoles of dNTPs (Pharmacia, Piscataway, NJ), 5% of the 
cDNA reaction, and 0.5 U of Taq polymerase (Boehringer Mann- 
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were subjected to denaturation  at 94~  for 2 min, followed by 30-60 
cycles consisting of denaturation at 94~  for I  rain, annealing at 
55~  for I min, and extension at 72~  for I min on DNA thermal 
cycler (model 480;  Perkin  Elmer Corp.,  Norwalk,  CT) (16). 
Sequencing.  PCIL products were electrophoresed on low melting 
point agarose gel (Bethesda  Research  Laboratories,  Gaithersburg, 
MD), isolated by excision, and purified  by phenol/chloroform ex- 
tractions.  The fragments were digested with EcoRI (New England 
Biolabs  Inc., Beverly, MA) in 40 gl volume at 37~  for 2-3 h, 
heat  inactivated  at  68~  for 5  min  and ethanol-precipitated  in 
2 M ammonium acetate. The pellet was resuspended in dH20 and 
ligated into EcoRI-digested M13mp19 (0.1/zg, New England Bio- 
labs, Inc.) with T4 DNA ligase and buffer (New England Biolabs 
Inc.) in a volume of 20 gl for 16 h at 15~  2-5/~1 of the ligation 
mixture was used to transform 100/zl of competent JM101 strain 
of Escherichia  coil  The transformation mixture was plated onto a 
lawn of overnight culture of  JM101 with isoprow1 B-D-thiogalac- 
toside (IPTG) and 5-Bromo-4-chloro-3-indoxyl  3-D-galactoside (X- 
gal) (Sigma Chemical Co.). White, well isolated plaques were picked 
and inoculated into 2 ml of an exponential phase culture ofJM101. 
After 5-16 h, the viral DNA was purified from the culture super- 
natant. The isolated DNA was resuspended  in 25 gl of dH20. Se- 
quencing was performed by dideoxy chain termination method (17) 
using Sequenase DNA sequencing kit (United States Biochemical 
Corp.,  Cleveland,  OH)  with 3sS-labeled dATP (SJ.1304;  Amer- 
sham Corp.). 
Results 
VAR1  Is H2-K-negative and Is Insensitive to Anti-A  CTL 
Clones.  The parental 6130 regressor tumor which is rejected 
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Figure 1.  VAR1,  the A-B-C + variant of the 6130 tumor, fails to ex- 
press K  k on the cell surface. 6130 and VAR1 were stained with second 
step antibody alone, 16-1-11  hybridoma culture supernatant (anti-K  k) plus 
second step antibody, or 15-5-5 hybridoma culture supernatant (anti-D  k) 
plus second step antibody as described in Materials and Methods. Cells 
were grown with  or without  IFN-y (30/~/ml,  48 h).  (Unfilled curves) 
Fluorescence after staining with second step antibody alone; (filled curves) 
fluorescence after anti-K  k or anti-D  k staining. 
Figure  2.  VAIL1 tumor cells 
fail to express detectable amounts 
of K  k mRNA, consistent with 
the lack of K  k protein expression. 
RNA from 6130 and VAR1  were 
reverse transcribed into cDNA and 
PCR performed with Kk-specific 
or B-actiu specific primers. No 
Kk-specific band  is  visible for 
VAR1. 
by normal mice after  transient  growth has  at  least  three 
CTL-defined antigens designated as "A", "B", and "C" (2). 
The progressor variant VAR1 is a variant of 6130 that was 
negatively selected  using anti-A and anti-B CTL clones. Pheno- 
typically,  this variant was previously shown to be H2-K  k- 
negative and insensitive to lysis by both the anti-A and anti-B 
CTL clones (2). To confirm this phenotype, immunofluores- 
cent staining and cytolysis assays were performed. Unlike the 
parental 6130 tumor, VAR1 was not detectably stained by 
an anti-K  k mAb, even when pretreated with IFN-% but did 
retain expression  of the H-2D k molecule (Fig.  1). We also 
looked for transcription of the K k gene by PCR. First-strand 
cDNA was synthesized from total RNA extracted from 6130 
and VAR1. PCR performed with Kk-specific  primers showed 
no detectable message  for the K k molecule in VAR1  cells 
(Fig. 2). Furthermore, VAR1 is insensitive to cell-mediated 
killing by each of two anti-A specific CTL clones, BS1 and 
PD4,  and is also insensitive to anti-B  CTL (2). However, 
VAR1 is sensitive to lysis by the anti-C clone SS1 (Fig. 3). 
These data indicate that either the A  antigen and the K k 
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Figure  3.  VAR.1  tumor cells are insensitive to anti-A CTL clones but 
still retain sensitivity to lysis by an anti-C clone. Both BS1 (A) and PD4 
(B) CTL clones specifically lyse A antigen-positive targets, but not A 
antigen-negative VAR1, VAR4, or 6138 cells. The SS1 clone (C) lyses C 
antigen-positive VAR1 and VAR4, but not the C antigen-negative  VAR3 
cells. 
935  Seung  et al. molecule are concomitantly lost, or that the K ~ molecule is 
required for presentation of the A and B antigens. It is un- 
likely that VAR,1 can revert  to K ~ expression  and thereby 
present the A antigen on its cell surface since the VAR1 tumor 
cells we used in this study repeatedly failed to express surface 
K ~ or message for K ~ even after IFN-3/stimulation during 
a 4-too period.  Also,  VAR1  tumor ceUs reisolated from a 
mouse remained K~-negative  (data not shown). Neverthe- 
less, we do not know the molecular basis of the K ~ mole- 
cule loss and whether all of the abnormalities described  for 
VAP,1 can be reversed by making VAR1  express  K ~ after 
transfection.  So far, we have not succeeded in generating K ~- 
expressing VAR1  cells. 
VAR1 Primes.for  a Response against the A Antigen.  To de- 
termine if VAR1 stiU expresses the A antigen, mice were im- 
munized with 6130,  VAR1,  and VAR4  (A- B +  C +,  K ~  + 
6130 variant [2]) tumor cells intraperitoneally. After 7-10 d, 
spleens were harvested from the immunized mice, and MLTC 
cultures set up with 6130 tumor cells as the stimulators. Re- 
sponder cells from both 6130 and VARl-immunized mice 
showed a strong secondary anti-A response, whereas responder 
cells from VAR4-immunized mice showed an anti-B response 
(Fig. 4, A-C).  Thus, although VAR1 cannot present the A 
antigen on its surface, presumably because of the lack of K ~ 
molecules,  it still primes for an immune response  to the A 
antigen. To confirm that the apparent A-specific priming re- 
quires immunizations with a tumor of the 6130 tumor lin- 
eage, mice were immunized with 6132A, a K ~+ UV-induced 
tumor with noncrossreacting CTL-defined antigens. MLTC 
cultures were established with 6130 tumor cells as stimulators. 
As seen in Fig. 4 D, no anti-A cytolytic activity was evident. 
To determine if presentation of the A antigen on the target 
surface is required to induce an effective secondary response, 
spleen ceils from 6130 and VARl-immunized mice were used 
in MLTC cultures with VAR1 tumor cells as stimulators. This 
resulted in the absence of an effective secondary response  to 
the A antigen (Fig. 4, E and F). Surprisingly, no anti-C re- 
sponse was evident. Anti-C clones could, however,  be iso- 
lated after cloning anti-VAR1 CTL lines (P. Ward, unpub- 
lished data). 
6130 and VAR1, but Not VAR4, Induce a Dominant V~13 + 
PEL Proliferation.  Whereas our priming assays  indicated that 
VAR1 cells stimulate a response  against the A antigen, we 
analyzed further the nature of the response by characterizing 
the TCR of the responding T  ceils, since we have recently 
determined that the A antigen induces T cells with unique 
chain sequences  (12). 
TCR genes encoding ~ chains elicited in the response to 
6130 tend to employ VB13, D~1.1, and JBI.1 gene segments. 
In addition, the genes encode characteristic CDR3  amino 
acids that are not employed by T  ceUs responding to other 
tumors with noncrossreacting antigens (12). We found that 
VAR1  (A-B-C +) induces T  cells expressing similar TCR 
~/chains to those associated with the A antigen-specific re- 
sponse  to  6130  (A+B+C*).  Specifically, VAR1  induces a 
CD8 + PEL response  that is predominantly VB13 + as as- 
sessed by flow cytometry (Fig.  5, Table 1). DNA sequence 
analysis revealed that the VARl-induced V~/13  + cells were 
also oligodonal. 18 of 19 PCR isolates derived from VAR1- 
induced T  cells utilized one of four CDR3 sequences  (El- 
E3, E4-E9, D1-D5, and D6-D9; Fig. 6 A). Two of these se- 
quences,  those shared by isolates D6-D9 and D10, are iden- 
tical except  for a single nucleotide, which could represent 
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Figure  4.  Although insensitive to killing by anti*A CTLs, VAR1 tumor 
cells prime in vivo for an anti-A response in vitro. Mice were immunized 
with 6130 (A and E), VAR1 (B and F), VAR4 (C), or 6132A tumor cells 
(D). Spleen cells of these mice were tested in an MLTC. (A-D) Responders 
stimulated with 6130 tumor cells.  (E and F) Responders stimulated with 
VAR1 tumor cells. 6130 and VAR1 immunized mice demonstrate a strong 
anti-A response (A and B). VAR4-immunized mice show anti-B response 
(C), whereas 6132A immunized mice show no significant killing (D). 6130 
and VAIL1 immune responders stimulated with VAIL1 tumor cells fail to 
generate an anti-A response (E and F). 
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Figure  5.  6130 and VAR1, but not VAR4 or other tumor cells induce 
a strong V~13 + PEL response among the CD8 § T  cell popuhtion. PELs 
were induced and stained as described in Materials and Methods. The re- 
sponse to 6138 tumor cells is shown as being representative for a non-6130 
lineage tumor. 
936  MHC  Class I  Loss Tumor  Escape Variant Induces Specific CD8 §  T  Cells Table  1.  Significant  Increase of V/Y13 + CD8 + T  Lymphocytes  Induced by 6130 and VARI  but Not other Tumor Cells 
Antigen  Percent VB13 + of CD8 §  No.  mice tested  Percent V/~13 + of CD4 +  No.  mice tested 
6130"  42.3  •  4.7*  10  1.9  +  0.3S  7 
VAR1 II  28.3  •  2.2~  5  4.0  2 
VAR4 q  8.2  •  0.4  3  1.7  2 
6138"  6.9  _+  2.8  3  2.3  2 
Normal spleen  4.4  •  0.2  3  1.0  •  0.4  3 
* From reference 12. The data is presented  here for comparison. 
These values are significantly different from other values at p  <0.05, as determined by a 2-tailed Student t test. 
S The values are the mean •  SEM. 
I1 A-B-C*, K  ~-  variant  of 6130. 
I A-B+C +, K~.  variant of 6130. 
PCR error. All used the D/~1.1 gene segment,  and 8 out of 
19 used the J/~1.1 gene segment,  which was also prevalent 
among the 6130-induced  V/313 + cells (18  out of 26)  (12). 
At  the amino acid  level,  the CDR3  regions  of the J/51.1 + 
/3 chains  (D  and  E  isolates)  were also  similar  to  those of 
J/31.1 + T  cells induced by 6130. In each case, a character- 
istic CDR3 length of 9 amino acids was employed (Fig. 6 
B). Isolates D1-D5 and El-E3 each share seven out of nine 
amino acids with the CDR.3 sequence of the 6130-specific 
anti-A CTL clone BS1, which had been sequenced previously 
A 
TCR I~ junctional region 
PCI~  isolates  ~  ~--V ......  N  D~--~  N  ........  -J-  ........... 
c  A  S  S  S  O  A  t~  ?  S  V  s 
D 1  ,D2,D3,D4,D5  VI3  ]  3--TGTGCCAGCAGTTT  ACA  AGCA  AACACAGAAGTCTTC--J~  ].  ] 
C  A  S  K  G  Q  T  N  T  E  V  F 
s  V~]~--TGTGCCAGCA  A  GGGACAG  ACA  AACACAGAAGTCTTC-  -,J~  ].  ] 
C  A  S  S  R  Q  S  Q  N  T  L 
I:4,E5,E6,ET.F8,E9  V~|  3--TGTGCCAGCAG  CC  GACAG  AGTCAAAACACCTTG  -  -J~  1.4 
C  A  S  S  F  G  G  E  D  T  Q 
D6,D7,D8,D9  V~  ]  3-  -TGTGCCAGCAGTTTC  GG  AGGGG  AA  GACACCCAG~-J~2.5 
C  A  S  S  F  G  G  E  D  T  Q 
DI0  V~  }  3--TGTGCCAGCAGTTTC  GG  AGGGG  AT  GACACCCAG--J~2.5 
D~  ].  ]  GGGACAGGGGGC 
B 
FR3  CDR3  FR4 
v  s--c  Liiiii iiiiil  liiiiiiii iiiiii/!i ii iiiiiltiii iiii  
67  0  78  44  94  100  100  100  100 
D -Ds  v  3--c  s  Fsl  =  I:iii!A!:iiii! li  
28  0  78  44  94  1  O0  1  O0  1  O0  1 O0 
0  0  78  33  94  100  100  100  100 
Figl,  re  6.  Sequence analysis of VB13  + 
TCR/5 chains obtained by PCR of mRNA 
from T  cells responding  in vivo  to  the 
VAR1 tumor. (.4) Sequences  of nucleotides 
and translated amino acids in single letter 
code.  Only the junctional sequences are 
shown. Sequences  upstream of those shown 
were identical to those previously  published 
for the V/313 gene segment (39) and those 
downstream of those shown were identical 
to those previously published for the indi- 
cated J/~ gene segments (40) and for a por- 
tion of the C/9 segment (40, 41). The 3' 
boundary of the VB13 gene segment is ar- 
bitrary and based on comparison between 
these  and previously published VB13 se- 
quences. The 5' boundaries of the JB gene 
segments are based on comparison to their 
known germline sequences  (40, 41). All iso- 
lates employed a portion of the DBI.1 seg- 
ment (sequence  below [42]) and are aligned 
accordingly. Nucleotides between the V and 
D gene segments and between the D and 
J gene segments are presumed N region in- 
sertions. (B) Comparison of the translated 
amino acid sequences of the CDIK3 regions 
of PCR isolates utilizing J/31,1 (D and E 
isolates)  from  this  paper  (.4)  with  the 
CDR3 sequence of the anti-A CTL clone 
BS1 (12). (Light shading)  Similarity with the 
CDR3 regions of 18 JBI.1 + PCR isolates 
amplified from PEL responding to the 6130 
tumor in vivo (12). (Dark shading)  Increased 
similarity. The numbers below each CDR3 
amino acid indicate the percentage of the 
18 anti-6130 PCR isolates sharing that par- 
ticular amino acid at each position with the 
anti-A clone BS1, derived the 6130-immune 
mice, and with clones El-E3 and DI-D5 
from VARl-immune mice. 
937  Seung et al. (12). The numbers below each amino acid in Fig. 6 B indi- 
cate the degree of identity to previously sequenced PCR iso- 
lates amplified from PEL reacting to the A  antigen of the 
parental 6130 (12). The values are expressed as the percentage 
of 6130-induced J~1.1 + isolates  (18 total) possessing the in- 
dicated amino acid at each position. The similarities in CDR3 
sequences listed above, in addition to the cellular data, sug- 
gest that the T  cells responding to the different tumors are 
recognizing similar,  if not the same, antigen. Thus, VAR1, 
which fails to display the A antigen on its surface, nonethe- 
less induces T cells bearing TCR which in many ways mimic 
those of the anti-A VB13 + cells induced by the 6130 tumor. 
V#13 + PEL Induced by VARI  Are Not Cytolytic.  PELs 
induced by 6130 respond specifically to the A antigen, despite 
the presence of the other independent B and C antigens (Fig. 
7 A).  Although VAR1  induces a  strong V~13 §  PETE, re- 
sponse with TCR sequences indicative of A-antigen specifi- 
city (Figs. 5 and 6), A-specific killing was not evident by these 
PELs  (Fig.  7  C).  Therefore, we sought  to determine the 
specific  cytolytic activity of VARl-induced V/313 + PELs. 
V/313" ceils from anti-6D0 and anti-VAR1 PELs were sorted 
to 99% purity (data not shown). The sorted cells were tested 
for their cytolytic activity The VARl-induced V~13 § CTLs 
displayed no significant cytolytic activity (Fig.  7 D). 6130- 
induced V~13 §  CTLs,  on  the  other  hand,  killed VAR3 
(A+B*C -  6130 variant [2]) but not VAR4 (A-B+C +) (Fig. 
7 B) (12). 
VAR1 may either inhibit or reverse the acquisition of the 
cytolytic phenotype. The ability of VAR1 cells to restimu- 
late cytolytic anti-C CTL clones in vitro (data not shown) 
argues against the notion that VAR1 reverses the cytolytic 
phenotype. However, the finding of VARl-induced expan- 
sion of VB13 + CD8 + PELs that lack cytolytic activity is 
consistent with the possibility that VAR1 cells inhibit the 
acquisition of the cytolytic phenotype. An alternative possi- 
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Figure  7.  CTLs induced by VAR1 in vivo do not lyse h  antigen-positive 
targets. 6130 induced PELs, non-sorted (A) and V~13 + CD8"  sorted (B), 
are specific for the A  antigen (12). VARl-induced PELs,  nonsorted (C) 
or V~/13 §  CD8 +  sorted  (D),  fail to exhibit anti-A specific  lysis. 
bility is that a target presenting the A antigen was required 
to allow anti-A T  cells to become fully cytolytic (Fig.  4). 
Discussion 
In this study, we show that loss of expression of one MHC 
class I restriction dement by a tumor expressing multiple 
antigens can allow escape from immune destruction by the 
host, even though the variant tumor remains sensitive to CTLs 
obtained exogenously which are directed against other an- 
tigens presented by retained MHC class I molecules. The re- 
sponse to the remaining target antigens seems to be prevented 
because the variant continues to induce a clonaUy restricted 
CD8 + immune response to a dominant antigen (A) that no 
longer serves as a target for CTL-mediated destruction. The 
evidence for this dominance of the immune response to the 
A antigen comes from two observations. First, VAK1, which 
is completely resistant to anti-A CTLs but is susceptible to 
anti-C CTLs (Fig.  3), could prime for the response to the 
A antigen (Fig. 4 B) as effectively as the parental 6130 tumor 
(Fig. 4 A). This priming was specific for the A antigen since 
the unrelated 6132A tumor failed to prime for an anti-A re- 
sponse (Fig.  4 D).  Furthermore, anti-A priming by VAK1 
was probably not caused by a lineage-specific helper antigen 
(18) since VAK4 (A-B*C ") failed to prime for an anti-A 
response (Fig.  4  C).  Second, VAR1,  like 6130,  induced a 
significant increase in V313 + CD8 + PELs in vivo whereas 
VAK4 did not (Fig. 5, Table 1). Sequence analyses of the V313 
CDR3s from VAKl-induced PELs revealed striking similar- 
ities with those of the A antigen-specific CDK3s of 6130- 
induced PELs and anti-A CTL clone (Fig. 6). Since the CDK3 
is closely correlated with antigen fine specificity (19-23), the 
similarities observed in the CDK3s collectively support the 
notion that the VB13 + CD8 + cells induced in the perito- 
neal cavity by VAK1 bear TCRs specific for the A antigen. 
These two observations (A-specific  priming and induction 
of clonally restricted V~13 + PELs characteristic of anti-A 
CD8 + response) strongly suggest that VAK1  continues to 
express the A  antigen even though it can no longer serve 
as a target, presumably because of loss of the K k molecule. 
The A antigen may be released from Kk-negative VAK1 
cells and picked up by Kk-positive host APCs which subse- 
quently induce A antigen-specific CD8 + T cells. Generally, 
antigens in  the extracellular fluid are taken up by APCs, 
processed and presented in association with MHC class II 
molecules, and induce CD4 ~ T  cells (24).  In contrast, en- 
dogenously synthesized antigens are processed in an intracel- 
lular compartment distinct from the MHC class II pathway, 
presented in association with MHC class I molecules, and 
induce CD8 + CTLs (25, 26). Thus, the two different path- 
ways largely determine whether CD4 + or CD8 + T cells are 
utilized in an immune response (25-27), e.g., CD8 ~ CTLs 
selectively respond to cells expressing viral or tumor-specific 
antigens. However, these two mechanisms of antigen pre- 
sentation may not be absolutely segregated. The existence 
of an APC that can process and present exogenous antigens 
in association with MHC class I molecules has been postu- 
lated (28), and described (29). It is not clear how an antigen 
938  MHC  Class I  Loss  Tumor  Escape Variant  Induces Specific CD8 §  T  Cells can impede the response to a different coexisting antigen even 
if the antigens are restricted by different restriction elements. 
For example,  we have shown previously (12) and here that 
a given antigen presented in the context of H-2 K k can block 
responses to another antigen presented by H-2 D k. Since the 
antigen remains immunodominant despite the loss of its re- 
stricting element from the tumor, it appears  that the host 
APCs are critically involved in the establishment ofimmuno- 
dominance. Immunodominance is also observed in response 
to the parental 6130 tumor (12), to other tumors with mul- 
tiple antigens (4),  and to multiple minor H  antigens (30). 
Whereas tumor variants become resistant to anti-A CTL 
whether the A  antigen or the K k molecule is lost, the im- 
mune response to the two types of variants and the effects 
of this response are quite different. The A antigen loss variant 
can induce immune responses  to the remaining target an- 
tigens followed by stepwise selection of further antigen loss 
variants until the tumor lacks a target molecule. By contrast, 
the K k loss variant VAR1 continues to induce a response  to 
the immunodominant A antigen, even though that antigen 
is no longer a target on the tumor cell surface. Thus, other 
target antigens remain on the tumor cell surface for poten- 
tial specific immune therapy even though there is no host 
response to these antigens. 
Overall, this study suggests a previously undescribed path- 
way for a tumor with multiple antigens to escape from im- 
mune destruction. In this pathway, a heritable variant causes 
the host to focus on responding to a tumor antigen that is 
no longer a target for destruction on the variant tumor. This 
focusing may also prevent the host from mounting an im- 
mune response to secondary antigens, thereby rendering an 
antigenic tumor unrecognizable to the host. For this mecha- 
nism of escape, loss of a single allele was apparently sufficient 
to convert an immunogenic regressor  tumor to a progressor 
variant, despite the existence  of another antigen presented 
by the progressor variant on a remaining MHC allele. Loss 
of single MHC  class  I  alleles occurs rather frequently in 
common human tumors, and more so than the loss of all 
MHC expression  (7-11).  Therefore, the described  pathway 
may be commonly used for immune escape of human tumors. 
Our results may have important implications for interpreting 
the significance of the reported attraction of restricted T cell 
populations to certain progressively growing human cancers 
(31). Such attraction may occur even though the infiltrated 
cancer may not be a sensitive target for the attracted T cells. 
Finally, transfecting low MHC-expressing tumors with genes 
encoding the MHC allele that present tumor-associated an- 
tigens (32-35)  or IFN-3' (36-38)  have yielded effective im- 
munogens against the untransfected parental tumors since 
they remained susceptible to lysis by the induced CTLs. Such 
protocols may not be feasible with tumors, such as VAR1, 
which are completely resistant to lysis by the dominant antigen- 
specific CTLs even after stimulation with IFN-  7. However, 
it may be feasible to override the effects of the dominant an- 
tigen in MHC class I allelic loss variant by depleting the dom- 
inant T cell subsets that are induced (e.g.,  the V~13 popula- 
tion in the case of the VAR1  tumor) or by immunization 
with variants that have lost the immunodominant antigen 
rather than just its restricting element. Such treatment may 
well enhance the CTL response to antigens retained by the 
escape variants. 
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